Sage Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Sage Therapeutic
SAGE Stock  USD 8.68  0.02  0.23%   
Sage Therapeutic's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Sage Therapeutic's valuation are provided below:
Gross Profit
-138.3 M
Market Capitalization
544.9 M
Enterprise Value Revenue
2.7097
Revenue
47.4 M
Earnings Share
(4.89)
There are over one hundred nineteen available fundamental trend indicators for Sage Therapeutic, which can be analyzed over time and compared to other ratios. Investors should ensure to double-check all of Sage Therapeutic's current performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 2 B. The current year's Enterprise Value is expected to grow to about 1.8 B

Sage Therapeutic Total Revenue

39.18 Million

Check Sage Therapeutic financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sage Therapeutic's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.3 M, Interest Expense of 17.1 M or Selling General Administrative of 151.4 M, as well as many indicators such as Price To Sales Ratio of 7.6, Dividend Yield of 0.0 or PTB Ratio of 0.74. Sage financial statements analysis is a perfect complement when working with Sage Therapeutic Valuation or Volatility modules.
  
Build AI portfolio with Sage Stock
Check out the analysis of Sage Therapeutic Correlation against competitors.
For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.

Sage Therapeutic Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets852.2 M547.2 M683.1 M
Slightly volatile
Other Current Liabilities42.9 M57.6 M34.4 M
Slightly volatile
Total Current Liabilities60.8 M71.6 M48.9 M
Slightly volatile
Property Plant And Equipment Net11.9 M11.6 M9.6 M
Slightly volatile
Accounts Payable11.6 M12.7 M9.4 M
Slightly volatile
Cash77 M81 M216.9 M
Pretty Stable
Non Current Assets Total20.3 M15.9 M16.3 M
Slightly volatile
Other Assets7.3 M6.9 M3 M
Slightly volatile
Cash And Short Term Investments808 M504.4 M647.7 M
Slightly volatile
Common Stock Shares Outstanding47.3 M60.8 M41 M
Slightly volatile
Liabilities And Stockholders Equity852.2 M547.2 M683.1 M
Slightly volatile
Other Current Assets26.5 M17.7 M21.2 M
Slightly volatile
Total Liabilities72 M82.1 M59.7 M
Slightly volatile
Property Plant And Equipment Gross13.2 M12.4 M10.6 M
Slightly volatile
Total Current Assets832 M531.3 M666.9 M
Slightly volatile
Property Plant Equipment5 M3.3 M3.8 M
Slightly volatile
Other Liabilities109.2 K115 K536.6 K
Very volatile
Net Tangible Assets977.9 M1.4 B760 M
Slightly volatile
Common Stock Total Equity5.3 K6.9 K4.6 K
Slightly volatile
Capital Surpluse2 B3.8 B1.6 B
Slightly volatile
Non Current Liabilities Other8.5 M5.3 M5.5 M
Slightly volatile
Deferred Long Term Asset Charges512.8 K576.9 K629 K
Slightly volatile
Common Stock5.5 K6.9 K4.6 K
Slightly volatile
Net Invested Capital441.8 M465.1 M773.2 M
Slightly volatile
Net Working Capital436.7 M459.7 M766.1 M
Slightly volatile
Capital Stock6.3 K6.9 K5.4 K
Slightly volatile
Short and Long Term Debt Total15 M11.8 M28.9 M
Slightly volatile
Capital Lease Obligations15 M11.8 M28.9 M
Slightly volatile
Short Term Debt1.3 M1.3 M16.3 M
Slightly volatile
Net Receivables8.7 M9.1 M21 M
Pretty Stable

Sage Therapeutic Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.3 M1 M1 M
Slightly volatile
Selling General Administrative151.4 M216.4 M121.6 M
Slightly volatile
Other Operating Expenses375.7 M473.6 M302.2 M
Slightly volatile
Research Development218.4 M225.9 M175.9 M
Slightly volatile
Total Operating Expenses371.7 M464.2 M299 M
Slightly volatile
Preferred Stock And Other Adjustments1.8 M2.1 M2.3 M
Slightly volatile
Selling And Marketing Expenses53.9 M51.3 M25.5 M
Slightly volatile
Net Interest Income17.9 M31.7 M10.8 M
Slightly volatile
Interest Income17.9 M31.7 M10.8 M
Slightly volatile
Reconciled Depreciation2 M1 M1.2 M
Slightly volatile
Non Recurring22.2 M25 M27.2 M
Slightly volatile

Sage Therapeutic Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow68.7 M72.3 M212.2 M
Slightly volatile
Other Cashflows From Financing Activities2.4 M2.5 M14.2 M
Pretty Stable
Total Cash From Financing Activities10.1 M10.7 M171 M
Very volatile
End Period Cash Flow78.3 M82.5 M217.7 M
Pretty Stable
Stock Based Compensation66.2 M54.5 M49.2 M
Slightly volatile
Change To Netincome70.3 M69.1 M49 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio7.68.0004106
Pretty Stable
Days Sales Outstanding76.7980.8358875
Slightly volatile
Stock Based Compensation To Revenue1.261.32153.7871
Pretty Stable
Capex To Depreciation0.430.461.6778
Slightly volatile
EV To Sales6.016.322999.9046
Pretty Stable
Payables Turnover0.780.74370.1406
Slightly volatile
Sales General And Administrative To Revenue4.995.24748.6427
Slightly volatile
Research And Ddevelopement To Revenue5.25.477211.5133
Slightly volatile
Capex To Revenue0.0070.00740.0828
Very volatile
Cash Per Share11.768.30112.6972
Slightly volatile
Days Payables Outstanding46649110.5 K
Slightly volatile
Income Quality0.920.66690.8557
Very volatile
Current Ratio9.837.418910.8491
Slightly volatile
Receivables Turnover4.744.51530.9344
Slightly volatile
Debt To Equity0.01930.02540.0299
Slightly volatile
Capex Per Share0.00790.00830.0213
Pretty Stable
Revenue Per Share0.640.67872.6366
Very volatile
Interest Debt Per Share0.330.19480.3325
Pretty Stable
Debt To Assets0.01720.02160.0262
Slightly volatile
Graham Number81.8192.04100
Slightly volatile
Days Of Payables Outstanding46649110.5 K
Slightly volatile
Ebt Per Ebit1.080.92670.9884
Pretty Stable
Long Term Debt To Capitalization0.00390.00410.0192
Slightly volatile
Total Debt To Capitalization0.01880.02480.0288
Slightly volatile
Debt Equity Ratio0.01930.02540.0299
Slightly volatile
Quick Ratio9.897.418910.907
Slightly volatile
Net Income Per E B T1.061.090.9729
Slightly volatile
Cash Ratio1.071.13135.3115
Very volatile
Days Of Sales Outstanding76.7980.8358875
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.0218
Slightly volatile
Fixed Asset Turnover3.373.54239.8734
Pretty Stable
Debt Ratio0.01720.02160.0262
Slightly volatile
Price Sales Ratio7.68.0004106
Pretty Stable
Asset Turnover0.120.07540.1049
Very volatile
Gross Profit Margin1.020.7710.9628
Slightly volatile

Sage Therapeutic Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2 B1.2 B2.1 B
Slightly volatile
Enterprise Value1.8 B1.1 B1.9 B
Slightly volatile

Sage Fundamental Market Drivers

Cash And Short Term Investments504.4 M

Sage Upcoming Events

15th of February 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
15th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Sage Therapeutic Financial Statements

Sage Therapeutic stakeholders use historical fundamental indicators, such as Sage Therapeutic's revenue or net income, to determine how well the company is positioned to perform in the future. Although Sage Therapeutic investors may analyze each financial statement separately, they are all interrelated. For example, changes in Sage Therapeutic's assets and liabilities are reflected in the revenues and expenses on Sage Therapeutic's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Sage Therapeutic. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Revenue41.2 M39.2 M
Cost Of Revenue9.4 M9 M
Stock Based Compensation To Revenue 1.32  1.26 
Sales General And Administrative To Revenue 5.25  4.99 
Research And Ddevelopement To Revenue 5.48  5.20 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.68  0.64 
Ebit Per Revenue(10.48)(11.01)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
USOICredit Suisse X Links
ULTYTidal Trust II
CONYYieldMax N Option
When determining whether Sage Therapeutic is a strong investment it is important to analyze Sage Therapeutic's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sage Therapeutic's future performance. For an informed investment choice regarding Sage Stock, refer to the following important reports:
How To Invest In Sage
Details
Is Sage Stock a good investment?
Details
What is Sage Therapeutic's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Sage Therapeutic Correlation against competitors.
For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sage Therapeutic. If investors know Sage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sage Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.89)
Revenue Per Share
0.775
Quarterly Revenue Growth
0.78
Return On Assets
(0.36)
Return On Equity
(0.64)
The market value of Sage Therapeutic is measured differently than its book value, which is the value of Sage that is recorded on the company's balance sheet. Investors also form their own opinion of Sage Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Sage Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sage Therapeutic's market value can be influenced by many factors that don't directly affect Sage Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Sage Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sage Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sage Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY